Related references
Note: Only part of the references are listed.Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study
Ralf Gold et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study
Ralf Gold et al.
MULTIPLE SCLEROSIS JOURNAL (2017)
Central nervous system neuroinflammatory disorders in Asian/Pacific regions
Su-Hyun Kim et al.
CURRENT OPINION IN NEUROLOGY (2016)
Demyelinating diseases in Asia
Hirofumi Ochi et al.
CURRENT OPINION IN NEUROLOGY (2016)
Dimethyl fumarate in multiple sclerosis: latest developments, evidence and place in therapy
Ralf A. Linker et al.
THERAPEUTIC ADVANCES IN CHRONIC DISEASE (2016)
Characterizing absolute lymphocyte count profiles in dimethyl fumarate-treated patients with MS Patient management considerations
Robert J. Fox et al.
NEUROLOGY-CLINICAL PRACTICE (2016)
Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials
Vissia Viglietta et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2015)
Consensus Management of Gastrointestinal Events Associated with Delayed-Release Dimethyl Fumarate: A Delphi Study
J. Theodore Phillips et al.
NEUROLOGY AND THERAPY (2015)
Tolerability and Pharmacokinetics of Delayed-Release Dimethyl Fumarate Administered With and Without Aspirin in Healthy Volunteers
Sarah I. Sheikh et al.
CLINICAL THERAPEUTICS (2013)
Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis
Robert J. Fox et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Placebo-Controlled Phase 3 Study of Oral BG-12 for Relapsing Multiple Sclerosis
Ralf Gold et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Diagnostic criteria for multiple sclerosis: 2005 Revisions to the McDonald Criteria
CH Polman et al.
ANNALS OF NEUROLOGY (2005)
Share Paper
